Trending...
- Resident Inspect Joins Property Meld Nexus Network with API Integration
- Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
- RAATV Premieres Original Reality Series "The Access Index: Jackson" June, 19
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- From Blank Page to Published Book
- Larry R. Wasion's Jump Gate III RoadMaker Blends Cutting-Edge Sci-Fi with High-Stakes Space Exploration and Complex Technologies
- Ed, Edd n Eddy, Resident Evil, Anime Voice Actors Augment FAN EXPO Philadelphia Lineup
- American Mensa and Davidson Institute Join Forces To Strengthen Support for Profoundly Gifted Youth
- SpeedyIndex Rolls Out Automated API for Mass URL Verification, Solving the Backlink Blind Spot for SEO Agencies
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Pollock Begg Partner Joseph R. Williams Featured on 'CEOs You Should Know' Podcast
- Ashley Wineland's 'Love + Heartbreak' Tour Brings her Emotional and Empowering Album 'Wineland' to Nationwide Audiences
- People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
- With a Dream and a Team, Monalisa Okojie Is Empowering the Next Generation Through EXPOSE NGO
- Best Companies Group Launches Best Places to Work in PA Program
- American Properties Realty, Inc. Celebrates 2026 FAME Awards - Community of the Year - Heritage at South Brunswick
- Mel Blackwell to Keynote 2026 NSSF Marketing and Leadership Summit
- SmartCone and Samsung Launch RoadDefender™ to Enhance Real-Time Safety for Roadside Workers
- The Personal Development Industry Has a Blind Spot Says Global Personal Success Guru Omar L. Harris
- Kevin "Mr. Wonderful" O'Leary Begins New Universal Coin & Bullion Promotion of Gold and Silver
- Flamingo Compliance Launches Schengen Area Trip Planning Tools as New Digital Border Controls Take Effect
- HHS Announces Major Push to Address Psychiatric Drug Risks: CCHR Applauds Focus on Informed Consent and Safe Tapering
- PhaseZero Launches Eight AI Agents for Manufacturers and Distributors - Connecting Sales, Support, and Operations Teams Across Full Commerce Journey
- @tickerbitcoinbb and @girl_still_cute Announce the Arrival of SPROTO AEON BABY 1.0 – A New Chapter for the HarryPotterObamaSonic10Inu Universe
- Michigan Fitness Foundation Gifts EPEC Moves K–5 PE Curriculum Program to Educators during Michigan Moves Month
- Sidow Sobrino, the One and Only World's No.1 Superstar®, Launches Dangerous Joy
- Modern Site Builders Launches WolfResume.com, an AI Career Kit Built for ATS Hiring
- Slotozilla Expands Bonus Portfolio and Affiliate Reach Following iGB Barcelona 2026
- ThoroughCare Expands Remote Patient Monitoring with Withings Integration
- Wellsboro Earns Gold Bird Town Certification, Highlighting Conservation Leadership